| Dexamethasone/Neomycin Sulfate/ Polymyxin B Sulfate |
Ophthalmic Suspension | | | Develop a method to characterize in vitro release | | | 2018-02-15 |
| Ethinyl Estradiol/Norethindrone Acetate |
Tablet | II (Paddle) | 100 | Phosphate Buffer, pH 6.8, containing 0.07% w/v Triton X 100 | 900 | 5, 10, 20, 30, 45, 60 and 75 | 2018-02-15 |
| Mecamylamine HCl |
Tablet | | | Refer to USP | | | 2018-02-15 |
| Metyrosine |
Capsule | | | Refer to USP | | | 2018-02-15 |
| Nitisinone |
Tablet | II (Paddle) | 50 | Phosphate Buffer, pH 6.8 | 2 mg tablets: 500 mL | 10, 15, 20, 30, 45, 60, 75 and 90 | 2018-02-15 |
| Methscopolamine Bromide |
Tablet | | | Refer to USP | | | 2018-02-15 |
| Pregabalin |
Tablet (Extended Release) | II (Paddle) | 50 | 0.06 M HCl | 900 | 1, 2, 4, 6, 8, 10, 12, 16 and 24 hours | 2018-02-08 |
| Medroxyprogesterone Acetate (104mg/0.65ml) |
Injectable Suspension | | | Develop a method to characterize in vitro release | | | 2018-02-08 |
| Omeprazole (Orally Disintegrating) |
OTC Tablet (Delayed Release) | II (Paddle) | 100 | Tablets are pre-exposed to 500 ml of 0.1M HCL for 2 hrs and then 400 ml of 0.235M Na2HP04 is added to the medium. Adjust if necessary with 2 N HCI or 2 N NaOH to a pH of 6.8 | Acid stage: 500; Buf | Acid stage: 120; Buffer stage: 10, 20, 30, 45 and 60 | 2018-02-08 |
| Triamcinolone Acetonide |
Intra-Articular, For Suspension (Extended Release) | II (Paddle) | 75 | 0.3% SDS in 10 mM phosphate buffer, pH 7.2 + 0.02% sodium azide @35°C | 1000 | 1, 2, 4, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours | 2018-02-08 |
| Aliskiren Hemifumarate |
Capsule (pellet) | I (Basket) | 100 | 0.01 M HCl (degas) | 500 | 5, 10, 15, 20, 30 and 45 | 2018-02-08 |
| Letermovir |
Tablet | II (Paddle) | 75 | 25 mM Na Acetate Buffer, pH 4.5 with 0.6% Tween-80 | 900 | 10, 15, 20, 30, 45 and 60 | 2018-02-08 |
| Acalabrutinib |
Capsule | II (Paddle) with sinker | 50 | 0.1 M HCl | 900 | 5, 10, 15, 20, 30 and 45 | 2018-02-08 |
| Dolutegravir Na/Rilpivirine HCl |
Tablet | II (Paddle) | 75 | 1.0 % Tween 20 in 0.01 M HCl, pH 2.0 | 900 | 10, 15, 20, 30, 45 and 60 | 2018-02-08 |
| Betrixaban |
Capsule | II (Paddle) with sinker | 75 | 0.01 N HCl, (with addition of pepsin if gelatin crosslinking is observed) | 900 | 5, 10, 15, 20 and 30 | 2017-11-16 |
| Delafloxacin Meglumine |
Tablet | II (Paddle) | 60 | 0.05 M Phosphate Buffer, pH 7.4 (degassed) | 900 | 5, 10, 15, 20 and 30 | 2017-11-16 |
| Naproxen |
Suspension | | | Develop a dissolution method | | | 2017-11-16 |
| Abemaciclib |
Tablet | II (Paddle) | 75 | 0.01 N HCl | 900 | 5, 10, 15, 20 and 30 | 2017-11-16 |
| Bosentan |
Tablet (For Suspension) | II (Paddle) | 75 | 0.1 N HCl with 0.5% sodium dodecyl sulfate (SDS), pH 1.1 | 900 | 5, 10, 15, 20 and 30 | 2017-11-16 |
| Methylphenidate |
Tablet (Extended Release, Orally Disintegrating ) | II (Paddle) | 75 | Acid Stage: 0.1 N HCl; Buffer Stage: Phosphate Buffer, pH 6.8 | Acid Stage: 900 mL; | Acid Stage: 15, 30, 60, 120 minutes; Buffer Stage: 1, 2, 3, 4, 6 and 8 hours | 2017-11-16 |
